Carlumab
Carlumab (alternate identifier CNTO 888) is a discontinued human recombinant monoclonal antibody (type IgG1 kappa) that targets human CC chemokine ligand 2 (CCL2)/monocyte chemoattractant protein (MCP1). Carlumab was under development for use in the treatment of oncology and immune indications and was studied for application in systemic sclerosis, atherosclerosis, diabetic nephropathy, liver fibrosis and type 2 diabetes. Carlumab was being developed by Janssen Biotech prior to discontinuation in 2012 due to limited success in clinical trials.
Link from a Wikipage to another Wikipage
primaryTopic
Carlumab
Carlumab (alternate identifier CNTO 888) is a discontinued human recombinant monoclonal antibody (type IgG1 kappa) that targets human CC chemokine ligand 2 (CCL2)/monocyte chemoattractant protein (MCP1). Carlumab was under development for use in the treatment of oncology and immune indications and was studied for application in systemic sclerosis, atherosclerosis, diabetic nephropathy, liver fibrosis and type 2 diabetes. Carlumab was being developed by Janssen Biotech prior to discontinuation in 2012 due to limited success in clinical trials.
has abstract
Carlumab (alternate identifier ...... ed success in clinical trials.
@en
كارلوماب هو جسم مضاد وحيد النس ...... ية. طورته شركة جونسون وجونسون.
@ar
CAS number
915404-94-3
FDA UNII code
6TC1BB2EV9
KEGG
Wikipage page ID
33,023,919
page length (characters) of wiki page
Wikipage revision ID
991,648,740
Link from a Wikipage to another Wikipage
ATC prefix
none
@en
CAS number
ChemSpiderID
none
@en
KEGG
D09877
@en
mab type
mab
@en
source
u
@en
target
type
mab
@en
Verifiedfields
changed
@en
verifiedrevid
460,019,588
Watchedfields
changed
@en
wikiPageUsesTemplate
subject
hypernym
comment
Carlumab (alternate identifier ...... ed success in clinical trials.
@en
كارلوماب هو جسم مضاد وحيد النس ...... ية. طورته شركة جونسون وجونسون.
@ar
label
Carlumab
@en
كارلوماب
@ar